Skip to Main Content

In a clutch of lawsuits, three drug makers argue the federal government is wrong to insist they must provide discounts on medicines to pharmacies that work with hospitals and clinics that serve primarily low-income populations.

The claims made by AstraZeneca (AZN), Sanofi, (SNY), and Eli Lilly (LLY) follow a recent advisory opinion issued by the Department of Health and Human Services, which maintained drug companies were wrong to curtail price breaks required as part of the 340B drug discount program.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!